Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology and Medical Oncologist at Angeles del Carmen Hospital, shared a post on X:
”ADC linker stability.
Greater linker stability does not necessarily translate into better ADC outcomes.
Several successful ADCs use relatively unstable linkers, while more stable designs have shown inconsistent efficacy gains and unexpected toxicities.
Important reassessment of ADC biology and clinical translation.”
Title: Re-Evaluating Antibody-Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
Authors: R. Colombo, S. Seredick, S. D. Barnscher, J. R. Rich
Other Articles Featuring Diego A. Díaz-García on OncoDaily.
